Blog
Latest articles, insights, and updates from the blog.
Need help or want to reach readers?
Have a correction, provider question, or advertising inquiry? Reach the editorial team.
Ketamine Side Effects: What New Clinical Data Reveals
New clinical analysis examines side effect profiles and discontinuation rates for ketamine and esketamine. Here's what treatment-resistant depression patients should know.
NRx's Preservative-Free Ketamine Moves Through FDA Review
NRx Pharmaceuticals reports progress on its FDA application for a preservative-free ketamine formulation. What patients should know about this development.
Psychedelics Executive Order: What It Means for Ketamine Patients
A new executive order targeting psychedelic medicines is reshaping the regulatory landscape. Here's what ketamine therapy patients should understand.
BPL-003 Shows Lasting Relief in Treatment-Resistant Depression
New phase 2a data on BPL-003 shows sustained symptom reduction in treatment-resistant depression. What patients should know about this emerging therapy.
Ketamine Side Effects: What New Data Tells Patients
A new clinical review examines side effect profiles and discontinuation rates for NMDA antagonists like ketamine and esketamine. Here's what patients should know.
Ketamine Side Effects: What New Data Means for Patients
New clinical guidance on NMDA antagonist side effects and discontinuation rates gives patients and families sharper questions to ask before starting ketamine therapy.
How Doctors Choose Ketamine vs. Other TRD Treatments
New clinical guidance explains how psychiatrists choose between esketamine, ketamine, and brain stimulation for treatment-resistant depression patients.
Cambridge Joins UK's Growing Psychedelic Research Push
Cambridge University has added its weight to UK psychedelic research. Here's what this institutional shift means for patients considering ketamine therapy.
Esketamine's Role in Treatment-Resistant Depression Care
Where esketamine (Spravato) sits in 2026 treatment-resistant depression care: FDA-approved indications, response rates after SSRI failure, access barriers, and how it compares to generic IV and at-home options.
New Ketamine Nasal Spray Shows Lasting Depression Relief
Phase 2a trial results for BPL-003, a ketamine-based nasal spray for treatment-resistant depression, show sustained symptom reduction. Here's what it means.
BXCL501 Phase 2a Trial Targets Acute Stress & PTSD Prevention
A new DoD-backed Phase 2a trial tests BXCL501 for acute stress reactions and PTSD prevention. Here's what this means for patients exploring trauma treatment.
New PTSD Prevention Drug Trial Enrolls First Patients
A DoD-backed Phase 2a trial is testing BXCL501 for acute stress reactions and PTSD prevention. Here's what ketamine patients should understand.